Last updated: 2026-09-05 22:36:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Harrow, Inc. (HROW) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $38.58, with a market capitalization of $1.46B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $28.54 to $54.85. This page covers its latest market performance, valuation, price trends and company information.
$1.46B | |
$37.96 | |
$59.23 | |
$3.33 | |
$38.26 | |
195.23K | |
-- | |
-- | |
$54.85 | |
$28.54 | |
-- | |
-- |
Harrow, Inc. (HROW) last closed at $38.26 as of 2026-09-04 23:31:00, unchanged from the previous close of $38.26.
During the latest regular trading session, HROW traded between $3.33 and $59.23, with a volume of 195.23K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Harrow, Inc. (HROW) moved from $37.22 to $38.58, representing a gain of 3.64% ($1.36).
The stock traded between $37.72 and $38.74 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 391.85 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 38.1%
HROW is currently trading at $38.58, placing it 38.1% of the way from its 52-week low of $28.54 to its 52-week high of $54.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 373 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Harrow, Inc. (HROW) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.